Cargando…
MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
BACKGROUND AND PURPOSE—: This study aimed to assess the efficacy of modafinil, a wakefulness-promoting agent in alleviating post-stroke fatigue ≥3 months after stroke. We hypothesized that 200 mg of modafinil daily for 6 weeks would result in reduced symptoms of fatigue compared with placebo. METHOD...
Autores principales: | Bivard, Andrew, Lillicrap, Thomas, Krishnamurthy, Venkatesh, Holliday, Elizabeth, Attia, John, Pagram, Heather, Nilsson, Michael, Parsons, Mark, Levi, Christopher R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404401/ https://www.ncbi.nlm.nih.gov/pubmed/28404841 http://dx.doi.org/10.1161/STROKEAHA.116.016293 |
Ejemplares similares
-
Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial
por: Lillicrap, Thomas, et al.
Publicado: (2016) -
Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
por: Lillicrap, Thomas P., et al.
Publicado: (2018) -
Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue
por: Visser, Milanka M., et al.
Publicado: (2019) -
Peripheral Immune Cell Counts and Advanced Imaging as Biomarkers of Stroke Outcome
por: Pagram, Heather, et al.
Publicado: (2016) -
Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease
por: Gorman, Gráinne S., et al.
Publicado: (2015)